A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man
Open Access
- 1 May 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (9) , 2768-2776
- https://doi.org/10.1158/1078-0432.ccr-06-2362
Abstract
Purpose: Docetaxel (Taxotere), an important chemotherapeutic agent with shown activity in a broad range of cancers, is being investigated for use in combination therapies and as an antiangiogenic agent. Docetaxel exhibits a complex pharmacologic profile with high interpatient variability. Pharmacokinetic models capable of predicting exposure under various dosing regimens would aid the rational development of clinical protocols.Keywords
This publication has 34 references indexed in Scilit:
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 2006
- Docetaxel administration schedule: From fever to tears? A review of randomised studiesEuropean Journal Of Cancer, 2005
- Alterations of β‐tubulin isotypes in breast cancer cells resistant to docetaxelThe FASEB Journal, 2005
- DocetaxelDrugs, 2005
- A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid TumorsClinical Cancer Research, 2004
- DIFFERENT IN VITRO METABOLISM OF PACLITAXEL AND DOCETAXEL IN HUMANS, RATS, PIGS, AND MINIPIGSDrug Metabolism and Disposition, 2004
- Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapyEuropean Journal Of Cancer, 2004
- Taxane-Mediated Antiangiogenesis in Vitro Cancer Research, 2004
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 1999
- Physiological Parameter Values for Physiologically Based Pharmacokinetic ModelsToxicology and Industrial Health, 1997